Improving acute cardiac transplantation rejection therapy using ultrasound-targeted FK506-loaded microbubbles in rats
Open Access
- 12 August 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 7 (9) , 3729-3740
Abstract
Targeted delivery of immunosuppressants to allografts can increase the concentrations of drugs in pathological tissues, improve therapeutic effects and reduce unfavorable side effects. Therefore, we synthesized FK506-loaded microbubbles (FK506-MBs) for site-specific release of FK506 into transplanted hearts by the ultrasound-targeted microbubble destruction (UTMD) technique. The average particle size of FK506-MBs was 1.65 ± 0.32 μm and they had high drug loading and encapsulation efficiency. The in vivo drug concentration in transplanted hearts that were treated with FK506-MBs plus UTMD was about 1.64-fold higher than that in grafts that received free FK506 at the same dosage. The degree of graft rejection in the FK506-MB plus UTMD group was lower than those of other groups. Both infiltration of T cells and secretion of inflammatory cytokines were significantly reduced in the FK506-MB plus UTMD group. More importantly, the mean survival time of the grafts was significantly longer (16.00 ± 0.89 day) than those of the PBS group (6.66 ± 1.36 day) and the FK506 group (12.83 ± 1.17 day). In addition, we also found that the concentration of FK506 in whole blood was lower in the FK506-MB plus UTMD group than that in the FK506 group, which would be beneficial for reducing the side effects. Hence, our results showed that combining FK506-MBs with UTMD was an effective strategy to deliver FK506 to transplanted hearts, which can increase the local drug concentration and enhance its efficacy on rejection. Ultrasound-targeted drug release is safe and radiation-free, with great potential for clinical transformation, and could also be extended to the treatment of other graft rejection cases, such as liver transplantation, kidney transplantation and so on.Keywords
Funding Information
- National Natural Science Foundation of China (81530056, 81727805, 81471678, 81271582, 81671705, 81771851, 81701716)
- Henan University of Science and Technology (0118530300)
This publication has 48 references indexed in Scilit:
- Advances in Ultrasound Mediated Gene Therapy Using Microbubble Contrast AgentsTheranostics, 2012
- Therapeutic Ultrasonic Microbubbles Carrying Paclitaxel and LyP-1 Peptide: Preparation, Characterization and Application to Ultrasound-Assisted Chemotherapy in Breast Cancer CellsUltrasound in Medicine & Biology, 2011
- Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineeringPhysics in Medicine & Biology, 2009
- Ultrasound targeted microbubble destruction for drug and gene deliveryExpert Opinion on Drug Delivery, 2008
- Acute rejection after heart transplantationExpert Opinion on Pharmacotherapy, 2006
- Immunosuppression for heart transplantation: where are we now?Nature Clinical Practice Cardiovascular Medicine, 2006
- Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart RejectionThe Journal of Heart and Lung Transplantation, 2005
- TacrolimusDrugs, 2003
- Tacrolimus whole blood concentrations correlate closely to side‐effects in renal transplant recipientsBritish Journal of Clinical Pharmacology, 1999
- TacrolimusDrugs, 1993